Plus Therapeutics
PSTV
3 hedge funds and large institutions have $33.4M invested in Plus Therapeutics in 2013 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4% more capital invested
Capital invested by funds: $32.1M → $33.4M (+$1.28M)
0% more funds holding
Funds holding: 3 → 3 (0)
70% less call options, than puts
Call options by funds: $164K | Put options by funds: $542K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$143K |
| 2 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$134K |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$59K |
| 4 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$48K |
| 5 |
PC
Passport Capital
San Francisco,
California
|
-$42K |
PSTV Hedge Fund Activity: Q3 2013 in Review
3 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q3 2013, worth a combined $33.4M — up 4% from $32.1M a quarter earlier.
Fund positioning in PSTV was balanced in Q3 2013: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $143K.
- 3 institutional investors held Plus Therapeutics (PSTV) as of Q3 2013, unchanged from Q2 2013.
- Funds reported $33.4M of Plus Therapeutics stock for Q3 2013, up 4% quarter-over-quarter.
- 0 funds opened new Plus Therapeutics positions in Q3 2013 and 0 closed out.
- The largest Plus Therapeutics seller in Q3 2013 was Gilder Gagnon Howe & Co, an estimated $143K sold.
Based on aggregated 13F filings for Q3 2013.